NFKB1 and periodontitis: (161) used ginsenoside 3 (Rb3) to treat lPS-induced experimental periodontitis rats and found that Rb3 inhibited MAPK/AKT/NF-κB signaling pathway, improved inflammation and reduced alveolar bone resorption in rats.